#hepatocellular carcinoma

Checkpoint Immunotherapy Looks Promising for Operable Liver Cancer

Cabometyx is the third liver cancer drug approved in the past six months.

People with HIV who have higher viral load and worse immune function appear to be at higher risk for hepatocellular carcinoma.

A study found that people who had the largest increase in whole grain lowered their liver cancer risk by nearly 40 percent.

Seventy percent of liver cancer patients had either a partial response or stable disease.

Cabometyx is the third liver cancer drug approved in the past six months.

Rick George credits his spiritual life with seeing him through multiple health crises, including liver cancer.

Half of people with worse liver function responded well to immunotherapy.

Liver fat may be a driver of increased cancer risk associated with obesity.

A second immunotherapy option is now available for hepatocellular carcinoma.

A new study examines the clinical and economic impact of new direct-acting antivirals.

Study showed significant improvement in progression-free survival with lenvatinib compared to sorafenib.

Lenvima works as well as standard therapy for metastatic or unresectable cancer.